Volenrelaxin
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Volenrelaxin
- immunoglobulin g anti human serum albumin human lama glama γ chain v d j region fusion protein with peptide linker ggggq 5 fusion protein with 2 29 relaxin 2 human chain b fusion protein with peptide linker gggsggsggg fusion protein with relaxin 2 human chain a
- Immunoglobulin G, anti-(human serum albumin) (human-Lama glama γ-chain V-D-J region) fusion protein with peptide linker (GGGGQ)5 fusion protein with 2-29-relaxin 2 (human chain B) fusion protein with peptide linker (GGGSGGSGGG) fusion protein with relaxin 2 (human chain A)
- ly 3540378
- LY-3540378
- ly3540378
- Ly3540378
- LY3540378
- volenrelaxin
- Volenrelaxin
- volenrelaxin [INN]
- VOLENRELAXIN [USAN]
- volenrelaxin inn
- volenrelaxin usan
- volenrelaxina
- Volenrelaxina
- volenrelaxine
- Volenrelaxine
- CAS registry numbers
- 2653949-19-8
- ChEMBL ID
- CHEMBL6068449
- FDA ingredient codes (UNII)
- TVT9XLV5MU
- First in class
- No
- Orphan designation
- No
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Respiratory Tract Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000684
- Subject identifier
- D012140
- Condition
- Kidney Diseases
- Highest recorded phase
- 1
- Condition identifier
- HP:0000077
- Subject identifier
- D007674
- Condition identifier
- EFO_0000319
- Condition identifier
- EFO_0000684
- Condition identifier
- EFO_0003884
- Highest recorded phase
- 2
- Condition identifier
- HP_0000077
- Condition identifier
- MONDO_0004995
- Condition identifier
- MONDO_0005087
- Condition identifier
- MONDO_0005300
- Highest recorded phase
- 2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (3)
- A Study of LY3540378 in Healthy Participants
- A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
- Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
In development for (4)
- Cardiovascular disorder Phase 1
- Chronic kidney disease Phase 2
- Kidney disorder Phase 1
- Respiratory system disorder Phase 1